{"id":742230,"date":"2012-04-16T06:06:00","date_gmt":"2012-04-16T06:06:00","guid":{"rendered":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-and-endocyte-enter-exclusive-worldwide-agreement-to-develop-and-commercialize-phase-iii-cancer-candidate-vintafolide-ec145\/"},"modified":"2023-03-22T00:04:24","modified_gmt":"2023-03-22T04:04:24","slug":"merck-and-endocyte-enter-exclusive-worldwide-agreement-to-develop-and-commercialize-phase-iii-cancer-candidate-vintafolide-ec145","status":"publish","type":"news_item","link":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-and-endocyte-enter-exclusive-worldwide-agreement-to-develop-and-commercialize-phase-iii-cancer-candidate-vintafolide-ec145\/","title":{"rendered":"Merck and Endocyte Enter Exclusive Worldwide Agreement to Develop and Commercialize Phase III Cancer Candidate Vintafolide (EC145)"},"content":{"rendered":"<p>WHITEHOUSE STATION N.J. &#038; WEST LAFAYETTE, Ind.&#8211;(BUSINESS WIRE)&#8211;Merck, known as MSD outside the United States and Canada, (NYSE: MRK)        and Endocyte Inc. (NASDAQ: ECYT), today announced that they have entered        into an agreement to develop and commercialize Endocyte&#8217;s novel        investigational therapeutic candidate vintafolide (EC145). Vintafolide        is currently being evaluated in a Phase III clinical trial for        platinum-resistant ovarian cancer, (PROCEED trial) and a Phase II trial        for non-small cell lung cancer (NSCLC); both studies are also using        Endocyte&#8217;s investigational companion diagnostic agent, etarfolatide        (EC20).     <\/p>\n<p>       &#8220;Vintafolide is a promising and innovative late-stage cancer drug        candidate. In addition to pursuing the lead indication of        platinum-resistant ovarian cancer, Merck plans to further evaluate its        potential for treatment of multiple other cancer types,&#8221; said Peter S.        Kim, executive vice president and president Merck Research Laboratories.        &#8220;This agreement underscores our strategy of building a portfolio of        oncology therapeutics that employ a companion diagnostic to facilitate        selection of those patients most likely to respond to treatment.&#8221;     <\/p>\n<p>       Under the agreement, Merck, through a subsidiary, will gain worldwide        rights to develop and commercialize vintafolide. Endocyte will receive a        $120 million upfront payment and is eligible for milestone payments of        up to $880 million based on the successful achievement of development,        regulatory and commercialization goals for vintafolide for a total of        six cancer indications. In addition, if vintafolide receives regulatory        approval, Endocyte will receive an equal share of the profit in the        United States (U.S.) as well as a double digit percentage royalty on        sales of the product in the rest of the world. Endocyte has retained the        right to co-promote vintafolide with Merck in the U.S. and Merck has the        exclusive right to promote vintafolide in the rest of world. Endocyte        will be responsible for the majority of funding and completion of the        PROCEED trial. Merck will be responsible for all other development        activities and costs and have all decision rights for vintafolide.        Endocyte remains responsible for the development, manufacture and        commercialization worldwide of etarfolatide, a non-invasive companion        diagnostic imaging agent that is used to identify folate receptor        positive tumor cells.     <\/p>\n<p>       &#8220;Following a rigorous selection process we believe Merck represents the        ideal strategic partner to achieve the full potential of vintafolide,        accelerating our development in numerous cancers,\u201d said Ron Ellis,        Endocyte\u2019s president and chief executive officer. &#8220;The agreement also        positions us well to build our own commercial infrastructure for        vintafolide in the U.S. and for etarfolatide worldwide.&#8221;     <\/p>\n<p>       Endocyte has completed three single arm studies of vintafolide in        patients with advanced platinum resistant ovarian cancer, non-small cell        lung cancer\u00a0and\u00a0solid tumors. In a randomized Phase II clinical trial        (PRECEDENT) comparing vintafolide plus pegylated liposomal doxorubicin        (PLD) versus PLD alone in women with platinum-resistant ovarian cancer,        vintafolide demonstrated a statistically significant delay in disease        progression or death in the overall population, with the largest        improvement observed in patients with all tumors imaged as positive for        folate receptor expression utilizing etarfolatide. Vintafolide in        combination showed limited additional toxicity versus standard therapy        with PLD alone. Common adverse events observed with this combination        were neutropenia, fatigue, mouth sores, and redness\/swelling\/pain on the        hands and feet.     <\/p>\n<p>       In March 2012, Endocyte announced that the European Union had granted        orphan drug status to vintafolide, and that the company planned to file        a marketing authorization application in the third quarter of 2012.     <\/p>\n<p>       Closing of the transaction is contingent upon obtaining Hart-Scott        Rodino clearance from the Federal Trade Commission.     <\/p>\n<p>       <b>Conference Call<\/b>     <\/p>\n<p>       Endocyte will host a conference call and webcast at 8:30am ET today to        discuss the agreement. To listen to the conference call, please dial        877-845-0711 or 760-298-5081. A replay of the call will be available        beginning at 11:30am ET today. To access the replay, please dial        855-859-2056 or 404-537-3406 and reference the conference ID 72307636.        The webcast can be accessed through Endocyte&#8217;s website at <a target=\"_blank\" href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&#038;url=http%3A%2F%2Fwww.endocyte.com&#038;esheet=50239281&#038;lan=en-US&#038;anchor=www.endocyte.com&#038;index=1&#038;md5=f04ecabdcb516a88f917020645a593ac\" rel=\"noopener\">www.endocyte.com<\/a>.     <\/p>\n<p>       <b>About Vintafolide (EC145)<\/b>     <\/p>\n<p>       Vintafolide is a proprietary, injectable, conjugate consisting of folate        (vitamin B9) linked to a potent vinca alkaloid chemotherapy agent,        desacetylvinblastine monohydrazide (DAVLBH). Vintafolide is designed to        preferentially target the chemotherapy agent to fast growing cancer        cells that actively take up folate via the folate receptor. The folate        receptor is expressed in a wide variety of cancers including ovarian,        NSCLC, breast, colon and kidney.     <\/p>\n<p>       <b>About Etarfolatide (EC20)<\/b>     <\/p>\n<p>       Etarfolatide is a folate-targeted molecular imaging agent that is being        developed as a non-invasive method to identify tumors that over-express        folate receptors. These tumors are the molecular target of Endocyte&#8217;s        folate-targeted therapeutic compounds such as vintafolide. To date,        etarfolatide has been administered to over 550 patients.     <\/p>\n<p>       <b>About the PROCEED Trial<\/b>     <\/p>\n<p>       The PROCEED trial is a Phase III randomized, double-blind clinical trial        evaluating vintalofide in combination with PLD compared to PLD plus        placebo for the treatment of folate-receptor positive platinum-resistant        ovarian cancer. The primary endpoint of the trial is progression-free        survival as measured by RECIST (Response Evaluation Criteria In Solid        Tumor) criteria in patients with folate-receptor positive tumors        assessed by etarfolatide imaging. Overall survival is a secondary        endpoint. The trial anticipates recruiting more than 400 patients at        approximately 150 sites in the U.S., Canada, Europe, and Asia. For        further information regarding the PROCEED trial please visit <a target=\"_blank\" href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&#038;url=http%3A%2F%2Fwww.clinicaltrials.gov%2Fct2%2Fshow%2FNCT01170650%3Fterm%3DPROCEED%26rank%3D1&#038;esheet=50239281&#038;lan=en-US&#038;anchor=http%3A%2F%2Fwww.clinicaltrials.gov&#038;index=2&#038;md5=37029c8b18fee0becbee09dfe8ae7aea\" rel=\"noopener\">http:\/\/www.clinicaltrials.gov<\/a>.     <\/p>\n<p>       <b>About Merck<\/b>     <\/p>\n<p>       Today&#8217;s Merck is a global healthcare leader working to help the world be        well. Merck is known as MSD outside the United States and Canada.        Through our prescription medicines, vaccines, biologic therapies, and        consumer care and animal health products, we work with customers and        operate in more than 140 countries to deliver innovative health        solutions. We also demonstrate our commitment to increasing access to        healthcare through far-reaching policies, programs and partnerships. For        more information, visit <a target=\"_blank\" href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&#038;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated&#038;esheet=50239281&#038;lan=en-US&#038;anchor=vip2-msd.com\/merckcom-migrated&#038;index=3&#038;md5=3691d8afe1730d9a52caebed13f2b722\" rel=\"noopener\">vip2-msd.com\/merckcom-migrated<\/a>        and connect with us on Twitter, Facebook and YouTube.     <\/p>\n<p>       <b>About Endocyte<\/b>     <\/p>\n<p>       Endocyte is a biopharmaceutical company developing targeted therapies        for the treatment of cancer and inflammatory diseases. Endocyte uses its        proprietary technology to create novel Small Molecule Drug Conjugates        (SMDCs) and companion imaging diagnostics for personalized targeted        therapies. The company&#8217;s SMDCs actively target receptors that are        over-expressed on diseased cells, relative to healthy cells. This        targeted approach is designed to enable the treatment of patients with        highly active drugs at greater doses, delivered more frequently, and        over longer periods of time than would be possible with the untargeted        drug alone. The companion imaging diagnostics are designed to identify        patients whose disease over-expresses the target of the therapy and who        are therefore more likely to benefit from treatment.     <\/p>\n<p>       <b>Merck Forward-Looking Statement<\/b>     <\/p>\n<p>       This news release includes \u201cforward-looking statements\u201d within the        meaning of the safe harbor provisions of the United States Private        Securities Litigation Reform Act of 1995. Such statements may include,        but are not limited to, statements about the benefits of the merger        between Merck and Schering-Plough, including future financial and        operating results, the combined company\u2019s plans, objectives,        expectations and intentions and other statements that are not historical        facts. Such statements are based upon the current beliefs and        expectations of Merck\u2019s management and are subject to significant risks        and uncertainties. Actual results may differ from those set forth in the        forward-looking statements.     <\/p>\n<p>       The following factors, among others, could cause actual results to        differ from those set forth in the forward-looking statements: the        possibility that all of the expected synergies from the merger of Merck        and Schering-Plough will not be realized, or will not be realized within        the expected time period; the impact of pharmaceutical industry        regulation and health care legislation in the United States and        internationally; Merck\u2019s ability to accurately predict future market        conditions; dependence on the effectiveness of Merck\u2019s patents and other        protections for innovative products; and the exposure to litigation        and\/or regulatory actions.     <\/p>\n<p>       Merck undertakes no obligation to publicly update any forward-looking        statement, whether as a result of new information, future events or        otherwise. Additional factors that could cause results to differ        materially from those described in the forward-looking statements can be        found in Merck\u2019s 2011 Annual Report on Form 10-K and the company\u2019s other        filings with the Securities and Exchange Commission (SEC) available at        the SEC\u2019s Internet site (<a target=\"_blank\" href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&#038;url=http%3A%2F%2Fwww.sec.gov&#038;esheet=50239281&#038;lan=en-US&#038;anchor=www.sec.gov&#038;index=4&#038;md5=6973fcc611bd245bcd4b69c861fa24eb\" rel=\"noopener\">www.sec.gov<\/a>).     <\/p>\n<p>       <b>Endocyte Forward-Looking Statement<\/b>     <\/p>\n<p>       Certain of the statements made in this press release are forward        looking, such as those, among others, relating to the company\u2019s        expectations for seeking regulatory approval and commercial launch of        its products, including any conditional marketing authorization from the        EMA, initiation of future clinical trials, and expectations for the        receipt of milestones, royalties or other profits from the partnership.        Actual results or developments may differ materially from those        projected or implied in these forward-looking statements. Factors that        may cause such a difference include risks that the company may        experience delays in the completion of its clinical trials (whether        caused by competition, adverse events, patient enrollment rates,        unavailability of Doxil, regulatory issues or other factors); risks that        data from its clinical trials may not be indicative of subsequent        clinical trial results; risks related to the safety and efficacy of the        company\u2019s product candidates, the goals of its development activities,        estimates of the potential markets for its product candidates, estimates        of the capacity of manufacturing and other facilities required to        support its product candidates, projected cash needs, and expected        financial results. More information about the risks and uncertainties        faced by Endocyte, Inc. is contained in the company\u2019s periodic reports        filed with the Securities and Exchange Commission. Endocyte, Inc.        disclaims any intention or obligation to update or revise any        forward-looking statements, whether as a result of new information,        future events or otherwise.     <\/p>\n<p>       Photos\/Multimedia Gallery Available: <a target=\"_blank\" href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&#038;url=http%3A%2F%2Fwww.businesswire.com%2Fcgi-bin%2Fmmg.cgi%3Feid%3D50239281%26lang%3Den&#038;esheet=50239281&#038;lan=en-US&#038;anchor=http%3A%2F%2Fwww.businesswire.com%2Fcgi-bin%2Fmmg.cgi%3Feid%3D50239281%26lang%3Den&#038;index=5&#038;md5=fff3f3992b03c304ac02fc447bd1747a\" rel=\"noopener\"><span class=\"bwuline\">http:\/\/www.businesswire.com\/cgi-bin\/mmg.cgi?eid=50239281&#038;lang=en<\/span><\/a>     <\/p>\n<p><p>       Media Contacts:<br \/>Merck<br \/>Ian R. McConnell, 973-901-5722<br \/>or<br \/>Endocyte<br \/>Tony        Russo, 212-845-4251<br \/>Martina Schwarzkopf, 212-845-4292<br \/>or<br \/>Investor        Relations Contacts:<br \/>Merck<br \/>Alex Kelly, 908-423-5185<br \/>or<br \/>Endocyte<br \/>Stephanie        Ascher, 212-362-1200     <\/p><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Merck, known as MSD outside the United States and Canada, (NYSE: MRK) and Endocyte Inc. (NASDAQ: ECYT), today announced that they have entered into an agreement to develop and commercialize Endocyte&#8217;s novel investigational therapeutic candidate vintafolide (EC145). Vintafolide is currently being evaluated in a Phase III clinical trial for platinum-resistant ovarian cancer, (PROCEED trial) and a Phase II trial for non-small cell lung cancer (NSCLC); both studies are also using Endocyte&#8217;s investigational companion diagnostic agent, etarfolatide (EC20). &#8220;Vintafolide is a promising and innovative late-stage cancer drug candidate. In addition to pursuing the lead indication of platinum-resistant ovarian cancer, Merck plans to further evaluate its potential for treatment of multiple other cancer types,&#8221; said Peter S. Kim, executive vice president and president Merck Research Laboratories. &#8220;This agreement underscores our strategy of building a portfolio of oncology therapeutics that employ a<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"inpsyde_pem_expiration_date":[],"inpsyde_pem_expiration_action":[],"footnotes":""},"tags":[53,289],"class_list":["post-742230","news_item","type-news_item","status-publish","hentry","tag-corporate-news","tag-press-release"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Merck and Endocyte Enter Exclusive Worldwide Agreement to Develop and Commercialize Phase III Cancer Candidate Vintafolide (EC145) - Merck.com<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-and-endocyte-enter-exclusive-worldwide-agreement-to-develop-and-commercialize-phase-iii-cancer-candidate-vintafolide-ec145\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Merck and Endocyte Enter Exclusive Worldwide Agreement to Develop and Commercialize Phase III Cancer Candidate Vintafolide (EC145) - Merck.com\" \/>\n<meta property=\"og:description\" content=\"Merck, known as MSD outside the United States and Canada, (NYSE: MRK) and Endocyte Inc. (NASDAQ: ECYT), today announced that they have entered into an agreement to develop and commercialize Endocyte&#039;s novel investigational therapeutic candidate vintafolide (EC145). Vintafolide is currently being evaluated in a Phase III clinical trial for platinum-resistant ovarian cancer, (PROCEED trial) and a Phase II trial for non-small cell lung cancer (NSCLC); both studies are also using Endocyte&#039;s investigational companion diagnostic agent, etarfolatide (EC20). &quot;Vintafolide is a promising and innovative late-stage cancer drug candidate. In addition to pursuing the lead indication of platinum-resistant ovarian cancer, Merck plans to further evaluate its potential for treatment of multiple other cancer types,&quot; said Peter S. Kim, executive vice president and president Merck Research Laboratories. &quot;This agreement underscores our strategy of building a portfolio of oncology therapeutics that employ a\" \/>\n<meta property=\"og:url\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-and-endocyte-enter-exclusive-worldwide-agreement-to-develop-and-commercialize-phase-iii-cancer-candidate-vintafolide-ec145\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck.com\" \/>\n<meta property=\"article:modified_time\" content=\"2023-03-22T04:04:24+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png\" \/>\n\t<meta property=\"og:image:width\" content=\"3056\" \/>\n\t<meta property=\"og:image:height\" content=\"1380\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"8 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-and-endocyte-enter-exclusive-worldwide-agreement-to-develop-and-commercialize-phase-iii-cancer-candidate-vintafolide-ec145\\\/\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-and-endocyte-enter-exclusive-worldwide-agreement-to-develop-and-commercialize-phase-iii-cancer-candidate-vintafolide-ec145\\\/\",\"name\":\"Merck and Endocyte Enter Exclusive Worldwide Agreement to Develop and Commercialize Phase III Cancer Candidate Vintafolide (EC145) - Merck.com\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\"},\"datePublished\":\"2012-04-16T06:06:00+00:00\",\"dateModified\":\"2023-03-22T04:04:24+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-and-endocyte-enter-exclusive-worldwide-agreement-to-develop-and-commercialize-phase-iii-cancer-candidate-vintafolide-ec145\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-and-endocyte-enter-exclusive-worldwide-agreement-to-develop-and-commercialize-phase-iii-cancer-candidate-vintafolide-ec145\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-and-endocyte-enter-exclusive-worldwide-agreement-to-develop-and-commercialize-phase-iii-cancer-candidate-vintafolide-ec145\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"News\",\"item\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news-archive\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Merck and Endocyte Enter Exclusive Worldwide Agreement to Develop and Commercialize Phase III Cancer Candidate Vintafolide (EC145)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/\",\"name\":\"Merck.com\",\"description\":\"Just another vip-msd.com site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Merck and Endocyte Enter Exclusive Worldwide Agreement to Develop and Commercialize Phase III Cancer Candidate Vintafolide (EC145) - Merck.com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-and-endocyte-enter-exclusive-worldwide-agreement-to-develop-and-commercialize-phase-iii-cancer-candidate-vintafolide-ec145\/","og_locale":"en_US","og_type":"article","og_title":"Merck and Endocyte Enter Exclusive Worldwide Agreement to Develop and Commercialize Phase III Cancer Candidate Vintafolide (EC145) - Merck.com","og_description":"Merck, known as MSD outside the United States and Canada, (NYSE: MRK) and Endocyte Inc. (NASDAQ: ECYT), today announced that they have entered into an agreement to develop and commercialize Endocyte's novel investigational therapeutic candidate vintafolide (EC145). Vintafolide is currently being evaluated in a Phase III clinical trial for platinum-resistant ovarian cancer, (PROCEED trial) and a Phase II trial for non-small cell lung cancer (NSCLC); both studies are also using Endocyte's investigational companion diagnostic agent, etarfolatide (EC20). \"Vintafolide is a promising and innovative late-stage cancer drug candidate. In addition to pursuing the lead indication of platinum-resistant ovarian cancer, Merck plans to further evaluate its potential for treatment of multiple other cancer types,\" said Peter S. Kim, executive vice president and president Merck Research Laboratories. \"This agreement underscores our strategy of building a portfolio of oncology therapeutics that employ a","og_url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-and-endocyte-enter-exclusive-worldwide-agreement-to-develop-and-commercialize-phase-iii-cancer-candidate-vintafolide-ec145\/","og_site_name":"Merck.com","article_modified_time":"2023-03-22T04:04:24+00:00","og_image":[{"width":3056,"height":1380,"url":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"8 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-and-endocyte-enter-exclusive-worldwide-agreement-to-develop-and-commercialize-phase-iii-cancer-candidate-vintafolide-ec145\/","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-and-endocyte-enter-exclusive-worldwide-agreement-to-develop-and-commercialize-phase-iii-cancer-candidate-vintafolide-ec145\/","name":"Merck and Endocyte Enter Exclusive Worldwide Agreement to Develop and Commercialize Phase III Cancer Candidate Vintafolide (EC145) - Merck.com","isPartOf":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website"},"datePublished":"2012-04-16T06:06:00+00:00","dateModified":"2023-03-22T04:04:24+00:00","breadcrumb":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-and-endocyte-enter-exclusive-worldwide-agreement-to-develop-and-commercialize-phase-iii-cancer-candidate-vintafolide-ec145\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-and-endocyte-enter-exclusive-worldwide-agreement-to-develop-and-commercialize-phase-iii-cancer-candidate-vintafolide-ec145\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-and-endocyte-enter-exclusive-worldwide-agreement-to-develop-and-commercialize-phase-iii-cancer-candidate-vintafolide-ec145\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https:\/\/vip2-msd.com\/merckcom-migrated\/news-archive\/"},{"@type":"ListItem","position":2,"name":"Merck and Endocyte Enter Exclusive Worldwide Agreement to Develop and Commercialize Phase III Cancer Candidate Vintafolide (EC145)"}]},{"@type":"WebSite","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/","name":"Merck.com","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/vip2-msd.com\/merckcom-migrated\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"6517a7b6-2946-4b27-8c1d-40f6d60d1ce8","news_item_aria_label":"","media_files":null,"document_path":"","file":""},"_links":{"self":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/742230","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":0,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/742230\/revisions"}],"wp:attachment":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/media?parent=742230"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/tags?post=742230"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}